Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Tomtebodvägen 23A, Solna, Stockholm, Sweden.
Department of Neuroscience, Karolinska Institutet, Solna, Sweden.
Alzheimers Res Ther. 2021 Mar 2;13(1):54. doi: 10.1186/s13195-021-00789-5.
Increased knowledge of the evolution of molecular changes in neurodegenerative disorders such as Alzheimer's disease (AD) is important for the understanding of disease pathophysiology and also crucial to be able to identify and validate disease biomarkers. While several biological changes that occur early in the disease development have already been recognized, the need for further characterization of the pathophysiological mechanisms behind AD still remains.
In this study, we investigated cerebrospinal fluid (CSF) levels of 104 proteins in 307 asymptomatic 70-year-olds from the H70 Gothenburg Birth Cohort Studies using a multiplexed antibody- and bead-based technology.
The protein levels were first correlated with the core AD CSF biomarker concentrations of total tau, phospho-tau and amyloid beta (Aβ42) in all individuals. Sixty-three proteins showed significant correlations to either total tau, phospho-tau or Aβ42. Thereafter, individuals were divided based on CSF Aβ42/Aβ40 ratio and Clinical Dementia Rating (CDR) score to determine if early changes in pathology and cognition had an effect on the correlations. We compared the associations of the analysed proteins with CSF markers between groups and found 33 proteins displaying significantly different associations for amyloid-positive individuals and amyloid-negative individuals, as defined by the CSF Aβ42/Aβ40 ratio. No differences in the associations could be seen for individuals divided by CDR score.
We identified a series of transmembrane proteins, proteins associated with or anchored to the plasma membrane, and proteins involved in or connected to synaptic vesicle transport to be associated with CSF biomarkers of amyloid and tau pathology in AD. Further studies are needed to explore these proteins' role in AD pathophysiology.
了解神经退行性疾病(如阿尔茨海默病)中分子变化的演变对于理解疾病的病理生理学非常重要,并且对于能够识别和验证疾病生物标志物也至关重要。虽然已经认识到了在疾病发展早期发生的几种生物学变化,但仍需要进一步描述 AD 背后的病理生理机制。
在这项研究中,我们使用基于多重抗体和珠的技术,在 307 名无症状的 70 岁的 H70 哥德堡出生队列研究参与者的脑脊液(CSF)中检测了 104 种蛋白质的水平。
首先,我们将所有个体中的总 tau、磷酸化 tau 和淀粉样蛋白β(Aβ42)的核心 AD CSF 生物标志物浓度与蛋白质水平相关联。有 63 种蛋白质与总 tau、磷酸化 tau 或 Aβ42 具有显著相关性。此后,根据 CSF Aβ42/Aβ40 比值和临床痴呆评分(CDR)将个体进行分组,以确定病理和认知的早期变化是否对相关性有影响。我们比较了分析的蛋白质与 CSF 标志物之间的相关性,发现 33 种蛋白质在根据 CSF Aβ42/Aβ40 比值定义的淀粉样蛋白阳性和阴性个体之间具有明显不同的相关性。在根据 CDR 评分分组的个体中,没有观察到关联的差异。
我们鉴定了一系列跨膜蛋白、与质膜相关或锚定的蛋白以及与突触小泡运输相关或连接的蛋白与 AD 中 CSF 生物标志物淀粉样蛋白和 tau 病理学相关。需要进一步的研究来探索这些蛋白质在 AD 病理生理学中的作用。